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ABSTRACT 
 
Background: Non-vitamin K antagonist oral anticoagulants (NOACs) have been 
proposed as an alternative to vitamin K antagonists (VKA) for atrial fibrillation (AF) 
patients. Some studies have proposed that well-managed warfarin therapy is still a valid 
alternative as efficacious as NOACs but the potential impact and absolute effect of 
NOACs in “real world” optimally management of VKA AF patients is unknown.  
Purpose: To estimate the potential absolute benefit in clinical outcome rates if the 
optimally anticoagulated “real-world” AF patients with acenocoumarol had been treated 
with NOACs. 
Methods: We included 1,361 patients stable on acenocoumarol with a time in therapeutic 
range of 100% for the previous 6 months and 6.5 years of follow-up. The estimation of 
clinical events avoided was calculated applying absolute risk reductions, relative risk 
reductions and hazard ratios from the pivotal clinical trials, relative to acenocoumarol.  
Results: Compared to acenocoumarol, the highest estimated event reduction for stroke 
was seen with dabigatran 150mg, with an estimated reduction of 0.53%/year. For major 
bleeding, the highest estimated reduction was seen with apixaban (0.88%/year). For 
mortality, the largest estimated reduction was with dabigatran 150mg (0.75%/year). In 
net clinical outcome, apixaban had the estimated highest reduction (1.23%/year). All 
NOACs showed significantly lower rates for intracranial haemorrhage.  
Conclusion In optimally acenocoumarol anticoagulated AF patients, estimated 
reductions in stroke, bleeding and net clinical outcomes with various NOACs are evident. 
NOACs would potentially show an improvement even amongst optimally VKA AF 
patients.  
Key words: non-vitamin K oral anticoagulants, vitamin K antagonists, atrial fibrillation, 
mortality, major bleeding, time in therapeutic range  
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ABBREVIATIONS 
 
AF: Atrial fibrillation  
 
ARR: Absolute risk reduction 
 
eGFR: estimated glomerular filtration rate 
 
ESC: European Society of Cardiology 
 
HR: Hazard ratio 
 
ICH: Intracranial haemorrhage 
 
INR: International normalized ratio 
 
NNT: Number needed to treat 
 
NOAC: Non-vitamin K oral anticoagulant 
 
OAC: Oral anticoagulation  
 
RRR: Relative risk reduction 
 
RW: Real-world 
 
TTR: Time in therapeutic range 
 
VKAs: Vitamin K antagonists 
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INTRODUCTION 
In patients with atrial fibrillation (AF), oral anticoagulation therapy (OAC) with 
vitamin K antagonists (VKAs) is highly effective for reducing the risk of stroke by 64% 
and all-cause death by 26%, compared with control(1). The effectiveness and safety of 
VKA treatment is related to the quality of anticoagulation, assessed by the average 
percentage of the time in therapeutic range (TTR). Patients who achieve high TTR 
(>70%) have lower mortality, thromboembolic events and major bleeding than patients 
with poor anticoagulation control(2,3). Indeed, poor TTR <40% confers a higher risk of 
stroke than those patients who are left untreated(4). For that reason, clinical guidelines 
recommended an individual average of TTR of 70% to maximize the efficacy and safety 
of VKA treatment(5). However, the VKAs show a narrow therapeutic window due to the 
high inter- and intra-patient variability related to multiple food and drugs-drugs 
interactions(6); therefore, frequent monitoring and dose adjustment are necessary to 
achieve an optimal TTR(7). 
Non-vitamin K oral anticoagulants (NOACs) have been developed as generally 
effective and safe alternative to VKAs in AF patients(8). Also, this effectiveness seems 
consistent across the range of stroke risk assessed by CHADS2. Nonetheless, many 
healthcare systems remain unenthusiastic to implement a first-line strategy with NOACs 
and it is often required to start AF treatment with a VKA and only if they do not have 
good TTR after 6 months of treatment, only then it is possible to switch to NOACs(9).  
Also, the real-world (RW) effectiveness and safety of NOACs in AF patients could 
be different from the efficacy and safety as shown in the main trials. The NOACs have 
been compared with warfarin, and in their respective Phase 3 trials, the mean TTR was 
64.0% with dabigatran(10), 62.2% with apixaban(11), 55.2% with rivaroxaban(12) and 
64.9% with edoxaban(13). Indeed, some studies have proposed that well-managed 
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warfarin therapy is still a valid alternative for AF patients and could be as efficacious as 
NOACs (14,15), but the potential impact and absolute effect of NOACs in “real world” 
optimally management of VKA AF patients is unknown. 
The main objective of our study was to estimate the potential absolute benefit in 
clinical outcome rates if the optimally anticoagulated “real-world” AF patients with 
acenocoumarol had been treated with NOACs.  
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METHODS 
Between May 2007 and December 2007, we recruited all consecutive outpatients 
with confirmed diagnosis of paroxysmal, persistent and permanent AF who were stable 
on acenocoumarol in our single anticoagulation centre in a tertiary hospital in Murcia, 
Spain. We selected only optimally managed AF patients with stable range of INR 
(between 2.0-3.0) for at least the previous 6 months and at entry all patients had TTR 
100% to ensure baseline homogeneity of the study cohort.  
AF patients with rheumatic mitral disease and prosthetic heart valve disease, with 
hemodynamic instability, hospital admission, acute coronary syndrome or surgical 
interventions in the preceding 6 months were excluded from the study. All patients 
provided signed informed consent to participation in the study. The study was conducted 
according the ethical principles of Declaration of Helsinki and Good Clinical Practice 
Guidelines and was approved by the Ethics Committee from University Hospital Morales 
Meseguer (Murcia, Spain).  
 
Data collection 
At baseline, clinical and demographic data were collected from all AF patients and 
included in a complete medical history. We included demographic information, data on 
cardiovascular risk factors and comorbidities. We also calculated the TTR after 6 months 
of entry. Stroke risk was calculated using the CHADS2 (Congestive heart failure, 
Hypertension, Age ≥ 75 years, Diabetes mellitus, Stroke or transient ischemic attack) and 
CHA2DS2-VASc [Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes 
mellitus, Stroke or transient ischemic attack, Vascular disease, Age 65-74 years and Sex 
category (female)] scores. Renal function was assessed at baseline visit. 
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Follow-up and clinical outcomes 
Follow-up was performed through visits to the anticoagulation clinic and started 
the day of the inclusion for 6.5 years. No patient was lost to follow-up. Adverse 
thromboembolic events (stroke/transient ischaemic attack) and myocardial infarction 
were collected. Death was classified as a fatal cardiovascular event (acute coronary 
syndrome, heart failure, lethal arrhythmia or sudden death, artery aneurysm rupture or 
stroke) or another nonvascular death fatal event. Major bleeding events were defined 
according to the 2005 International Society of Thrombosis and Haemostasis criteria(16) 
fatal bleeding or symptomatic bleeding in a critical anatomical site (intracranial, 
intraspinal, intraocular, retroperitoneal, intraarticular, pericardial or intramuscular with 
compartment syndrome) and/or bleeding causing a fall in Hb ≥20 g/L, or transfusion of 
≥2 units of whole blood or red blood cells. Net clinical outcome was defined as the 
composite of stroke, major bleeding and all mortality. 
 
Statistical analyses 
Quantitative variables were described using the mean ± standard deviation or 
median [interquartile range]. Categorical variables are expressed as percentages. Normal 
distribution of continuous variables was tested with the Kolmogorov-Smirnov method.  
 
Estimation of potential real-world effect of NOACs 
All adverse outcomes rates were calculated for optimally anticoagulated patients 
with acenocoumarol. The estimated rates (ie. the estimated rates if the patients had been 
treated with NOACs instead of acenocoumarol) of stroke, myocardial infarction, major 
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bleeding, gastrointestinal bleeding, intracranial haemorrhage, all-cause mortality, 
cardiovascular mortality and net clinical outcomes were calculated by multiplying the 
hazard ratios from the four pivotal trials (RE-LY(10), ARISTOTLE(11), ROCKET-
AF(12) and ENGAGE-AF(13) trials) by the reference rates of our optimally 
anticoagulated AF patients. Estimated rates according CHADS2 score (used in the 
respective trials) were also analyzed. We calculated the relative risk reduction (RRR), 
absolute risk reduction (ARR) and number needed to treat (NNT) of each adverse event 
with the reference event rates for patients exposed to warfarin and NOACs in each pivotal 
clinical trial. The ARRs, i.e. the absolute numbers of clinical events that theoretically 
might be avoided by using dabigatran, apixaban, rivaroxaban or edoxaban instead of 
acenocoumarol in optimally anticoagulated patients were calculated by multiplying RRRs 
from pivotal trials by the reference event rates for anticoagulated patients of our 
populations as Amin et al previously described(17). After that, the resulting absolute 
reduction numbers were employed to calculate NNT for each event.  
Comparisons between two event rates (real and estimated rates) with T-Test were 
performed and p-values with 95% confidence intervals were calculated. 
In all analyses, statistical significance was defined as p<0.05. Statistical analyses 
were performed with SPSS version 22.0 (SPSS Inc, Chicago, IL, USA) and MedCalc v. 
16.4.3 (MedCalc Software bvba, Ostend, Belgium) statistical packages for Windows.  
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RESULTS 
 
Baseline characteristics of optimally anticoagulated AF population and all pivotal 
clinical trials are shown in Table 1. 
Overall, data on 1,361 AF patients on acenocoumarol were analyzed (48.7% males, 
median age: 76 [IQR 71-81] years). The median TTR at 6 months after entry (median 
follow-up 214 days [IQR 213-2014]) was 80% (IQR 66-100). After 6.5 [IQR 4.3-7.9] 
years of follow-up, 130 patients had stroke (1.47%/year), 250 patients had major bleeding 
events (2.83%/year) and 551 patients died (6.23%/year). The distribution of bleeding 
events was as follow: 97 patients had gastrointestinal bleeding (1.10%/year) and 78 
patients had intracranial haemorrhage (0.88%/year). During the follow up, 136 patients 
(10% of the optimally managed AF population) discontinued oral anticoagulation 
therapy.  
The estimated effect of NOACs and the estimated reduction compared to 
acenocoumarol treatment are summarized in Table 2 and Figure 1.  
 
Thromboembolic events 
Stroke 
We estimated that the rates of stroke would be 0.94%/year (95%CI 0.76-
1.15%/year) for dabigatran 150 mg, 1.35%/year (95% CI 1.13-1.59 %/year) for 
dabigatran 110 mg, 1.16%/year (95%CI 0.97-1.40%/year) for apixaban, 1.25%/year 
(95%CI 1.05-1.50%/year) for rivaroxaban and 1.29%/year (95%CI 1.08-1.53%/year) for 
edoxaban. Compared to the optimally anticoagulated AF patients on acenocoumarol, only 
dabigatran 150 mg showed an estimated significant reduction with 0.53 stroke events per 
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100 patient-years (i.e. 47 strokes avoided over total sample) that would be avoided, giving 
NNT of 189 for stroke using dabigatran 150 mg instead of acenocoumarol. 
 
Myocardial infarction 
We observed a significant higher estimated rate of MI with dabigatran 150 mg 
(0.86%/year vs 1.19%/year; p=0.031) and dabigatran 110 mg (0.86%/year vs 1.10%/year; 
p=0.043) in comparison with the optimally management of acenocoumarol treatment. 
 
Bleeding events 
Major bleeding 
We estimated that the rates of major bleeding would be 2.63%/year (95%CI 2.34-
2.96%/year) for dabigatran 150 mg, 2.26%/year (95%CI 1.99-2.57%/year) for dabigatran 
110 mg, 1.95%/year (95%CI 1.69-2.23%/year) for apixaban, 2.94%/year (95% CI 2.63-
3.27%/year) for rivaroxaban and 2.26%/year (95% CI 1.99-2.57%/year) for edoxaban. 
Compared to the optimally anticoagulated AF patients on acenocoumarol, the highest 
significant event estimated reduction was observed with apixaban with 0.88 bleeding 
events per 100 patient-years (78 bleeding events avoided over total sample) that would 
be avoided giving NNT of 114 for bleeding using apixaban instead of acenocoumarol.  
 
Intracranial Haemorrhage 
All NOACs showed an estimated significant intracranial haemorrhage rate 
reduction in comparison with the optimally anticoagulation therapy with acenocoumarol. 
The estimated highest event reduction was observed with dabigatran 110 mg and 0.61 
intracranial bleeding events per 100 patient-years (i.e.54 bleeding events avoided over 
total sample) would be avoided using dabigatran 110 mg instead of acenocoumarol. 
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Gastrointestinal bleeding 
None of the NOACs showed an estimated significant reduction in gastrointestinal 
bleeding in comparison with optimally management of acenocoumarol treatment. 
However, dabigatran 150 mg (1.10%/year vs 1.65%/year; p=0.002) and rivaroxaban 
(1.10%/year vs 1.60%/year; p=0.004) demonstrated higher gastrointestinal bleeding 
events compared to acenocoumarol. 
 
Mortality 
We estimated that the rates of all-cause mortality would be 5.48%/year (95%CI 
5.10-5.88%/year) for dabigatran 150 mg, 5.67%/year (95%CI 5.29-6.07%/year) for 
dabigatran 110 mg, 5.54%/year (95%CI 5.15-5.94%/year) for apixaban and 5.73% 
(95%CI 5.34-6.13%/year) for rivaroxaban and edoxaban. Compared to the optimally 
anticoagulated AF patients on acenocoumarol, only dabigatran 150 mg showed an 
estimated significant reduction in mortality and 0.75 deaths per 100 patient-years (i.e. 66 
deaths avoided over total sample) would be avoided giving NNT of 133 for mortality 
using dabigatran 150 mg instead of acenocoumarol. Any NOAC showed an estimated 
significant reduction for cardiovascular mortality compared to acenocoumarol.  
 
Net clinical outcomes 
Apixaban and edoxaban had significantly lower estimated rates of net clinical 
outcomes in comparison with the optimally management of acenocoumarol treatment. 
The estimated highest event reduction was observed with apixaban with 1.23 net clinical 
events per 100 patient-years (i.e.109 composite adverse events avoided over total sample) 
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would be avoided, resulting in a NNT of 81 patients for the composite event using 
apixaban instead of acenocoumarol. 
 
Estimated effect of NOACs in high risk subgroup according to CHADS2 score 
In the high-risk subgroup (CHADS2 ≥3), apixaban showed the best composite 
reduction profile with an estimated significant reduction for stroke (1.97%/year vs 
1.38%/year; p=0.042), major bleeding (3.34% vs 2.53%; p=0.039) and intracranial 
haemorrhage (1.01%/year vs 0.29%/year; p<0.001). Dabigatran 150 mg, dabigatran 110 
mg and apixaban showed estimated significant risk reductions for intracranial 
haemorrhage through the different CHADS2 scores in comparison with acenocoumarol 
treatment (Figure 2, Supplementary Table 1). 
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DISCUSSION 
In an optimally anticoagulated acenocoumarol AF patients, potential estimated 
reductions in stroke, bleeding and net clinical outcomes with various NOACs are evident. 
All NOACs showed an expected significant reduction for intracranial haemorrhage. Thus, 
NOACs showed an improvement in both effectiveness and safety profile even in 
optimally VKA anticoagulated AF patients.  
Clinical trials are not always representative of RW settings because the randomized 
trials enrol highly selected patients with few elderly patients and closely monitored 
anticoagulation therapy and other comorbidities but their results are used to change the 
daily clinical practice (18). We observed differences in our baseline characteristics of AF 
population with older patients and higher comorbidities in comparison with pivotal trials 
except for ROCKET trial. Gaps in translation from trials to clinical practice inevitably 
occur and the effects of NOACs in RW could be very different (19). We observed higher 
rates of events in our population than in clinical trials. For example, in our optimally 
controlled AF population, we observed higher rates of ICH (0.88%/year) than in clinical 
trials (0.4-0.7%/year) but our rates were similar to other real-world studies (0.7-
1.3%/year) (20,21). Despite our patients have good TTR at the beginning of the registry, 
there were real-world patients with comorbidities and treated according usual clinical 
practice guidelines without additional care to be included in a registry. Clinical trials 
populations are really selected and with more additional visits and extra-care than daily 
clinical practice. This may reflect inherently different risk profiles between “real-world” 
and clinical trial cohorts. 
RW observational studies and meta-analysis found NOACs are overall safe and 
effective alternatives to warfarin treatment(22–24). Data from the Danish nationwide 
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databases reflected all NOACs seem to be safe and effective alternatives to warfarin 
without significant differences for ischaemic stroke and the risk of death and major 
bleeding were significant lower with apixaban(25). For example, Carmo et al.(26) 
performed a meta-analysis of 20 observational RW studies with more than 700,000 AF 
patients and showed that dabigatran was associated with a lower risk of ischaemic stroke. 
In our analysis, we observed dabigatran 150 mg was the drug that would have the highest 
estimated reduction of ischaemic stroke. In RELY clinical trial(10), the absolute 
difference between dabigatran150 mg and warfarin was 0.56%/year whereas in our data, 
we observed an estimated reduction of 0.53%/year in our optimally anticoagulated AF 
population. We observed in RW population similar potential estimated effect of 
dabigatran than in clinical trial. Recently, Korenstra et al.(27) showed that dabigatran in 
RW appears to be as effective as but significantly safer than acenocoumarol. Indeed, Lip 
et al.(28) conducted a RW comparison of major bleeding risk on NOACs and concluded 
that in newly anticoagulated AF patients, apixaban and dabigatran initiation was 
associated with significantly lower risk of major bleeding compared to warfarin. In our 
study, apixaban had the highest estimated reduction in major bleeding, even in the high-
risk AF patients (CHADS2≥3).  
The use of VKA therapy has many limitations due to drug-food and drug-drug 
interactions and its variable dose requirement with narrow therapeutic window(29). 
Indeed, in initiation period of VKA treatment, the TTR is lower than TTR measured after 
the warfarin inception period (30).Patients initiating VKAs had two-fold increased risk 
of ischaemic stroke in the first 30 days of use(3). NOACs have demonstrated rapid onset-
offset due to their predictable pharmacodynamic and pharmacokinetic action so NOACs 
could avoid this increase in thromboembolic events at the onset of OAC therapy. In our 
study, we have shown that NOACs could reduce adverse clinical outcomes even in 
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optimally management AF patients with TTR 100%. Indeed, Björck et al. (14,15) 
analyzed Swedish AF patients and compared the rates of clinical outcomes between well-
managed patients with TTR >70% or below and observed low risk of complications in 
well-managed group. They proposed VKA treatment with high TTR could be as effective 
as NOACs in preventing adverse outcomes. Contrary to the Swedish results, we observed 
that, even in patients with optimal anticoagulation management of VKA therapy (TTR 
100%), NOACs demonstrated a superior effect in efficacy and safety.  
The debate whether or not to switch stable warfarin patients to a NOACs will 
continue because this question cannot be answered until a clinical trial is performed 
comparing NOACs with TTR >70% (31), which is unlikely to happen. We observed in 
our optimally anticoagulated AF population lower stroke and bleeding rates than in 
pivotal clinical trials and despite this, NOACs still presented an estimated reduction effect 
for all clinical outcomes. 
Indeed, apixaban may offer the highest estimated favourable balance of efficacy 
and safety with the highest estimated reduction in net clinical outcomes. This effect was 
also estimated for high baseline risk assessed by CHADS2 ≥3 in comparison with 
acenocoumarol. Banerjee et al. (32) analyzed the net clinical benefit of NOACs using 
data from the Danish National Patient Registry and concluded that when the risk of 
bleeding and stroke are both high, NOACs appear to have a greater net clinical benefit 
compared to warfarin. 
The use of NOACs has been increasing since their introduction but the adoption 
into clinical practice has been slower than expected due to several factors. The ORBIT-
AF(33)and GARFIELD(34) registries showed that NOAC use ranged from 9 to 32% in 
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new-onset AF and 8 to 66%in patients with established AF, with considerable variation 
between countries(35).  
Several potential limitations are associated with NOAC prescription: health costs, 
adherence (and persistence) to NOAC treatment, monitoring requirements for renal 
function and a lower frequency of outpatient follow-up visits (which may be 
disadvantageous to some patients with multiple comorbidities). Many healthcare systems 
are currently unenthusiastic to implement a first-line strategy with NOACs due to the 
higher costs(9). Instead several cost-effective studies have shown additional health 
benefits in terms of quality-adjusted life-years of NOACs treatment compared with 
warfarin(36–38), many restrictions for use were observed in developed health systems 
and the authorization process of the prescription can be delayed (39). Low levels of 
adherence to NOAC are associated with bleeding and thromboembolic events, and 
cessation of oral anticoagulation is an important risk factor for stroke and mortality in AF 
patients(40,41). We also observed high rates of discontinuation therapy in the pivotal 
clinical trials, especially with edoxaban with 34% in both edoxaban and warfarin groups. 
In our cohort, we observed a rate of VKA discontinuation of 10%. 
 
Limitations 
This study is limited by its single center design and by a Caucasian based population. All 
statistical analyses were performed retrospectively although our dataset was collected 
prospectively. Although in pivotal clinical trials NOACs were compared with warfarin, 
we have used acenocoumarol because is the most common VKA used in Spain. The 
differences observed in anticoagulation control dependent on the type of VKA may result 
from a shorter half-life of acenocoumarol compared to warfarin (10 vs 36h). Warfarin 
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provides more stable anticoagulation with warfarin, but without significant differences 
on the time on therapeutic range in optimally managed AF patients. Patients are 
representative of a Spanish population and results might not be extrapolated to other 
countries. Moreover, the rate of stroke for CHADS2 score was not reported in the pivotal 
clinical trials but the rate of a combined endpoint of stroke and systemic embolism was 
published. We have infrequent rate of systemic embolism so we applied the combined 
rate for an estimation of the absolute number of stroke events avoided across CHADS2 
risk categories. ROCKET-AF clinical trial population had higher rate of comorbidities, 
risk factors, CHADS2 and HAS-BLED score in both, rivaroxaban and warfarin group. 
Although we did not perform a direct comparison between NOACs, some care should be 
taken when the clinical trials results were generalizing. We cannot perform a direct 
comparison using propensity score to homogenize the baseline characteristics then we 
assumed this limitation of our study. We did not compare differences between NOACs 
but we compared the differences between NOACs and optimal management of VKA 
therapy. Indeed, in ROCKET – AF clinical trials, the authors did not provide the hazard 
ratios or incidence rate of net clinical benefit for warfarin or rivaroxaban group, neither 
per protocol or intention to treat. In order to avoid the accumulation of errors by secondary 
analyses, we did not perform the comparison of net clinical benefit with rivaroxaban. For 
the adverse event comparison, we used the annual rate and assumed a constant and 
invariable adverse event rate and this may not be constant due the elderly and high 
comorbidities of real-world acenocoumarol population”. 
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CONCLUSIONS 
In an optimally anticoagulated acenocoumarol AF patients, potential estimated 
reductions in stroke, bleeding and net clinical outcomes with various NOACs are evident. 
All NOACs showed an expected significant reduction for intracranial haemorrhage. Thus, 
NOACs showed an improvement in both effectiveness and safety profile even in 
optimally VKA anticoagulated AF patients. 
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Figure 1 
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Figure 2 
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Table 1. Baseline clinical characteristics. 
 RE-LY11 ARISTOTLE12 ROCKET13 ENGAGE14 
Optimally 
Management 
 
Dabig
atran 
n=60
75 
Warf
arin 
n=60
22 
Apixa
ban 
n=912
0 
Warf
arin 
n=908
1 
Rivaro
xaban 
n=713
1 
Warfa
rin 
n=7133 
Edoxa
ban 
n=703
5 
Warf
arin 
n=703
6 
Acenoco
umarol 
n=1361 
Demographic          
Male sex 3840 
(63.2) 
3809 
(63.3) 
3234 
(35.5) 
3182 
(35.0) 
2831 
(39.7) 
2832 
(39.7) 
2669 
(37.9) 
2641 
(37.5) 
663 
(48.7) 
Age (years) 
71.5±
8.8 
71.6±
8.6 
70 (63-
76) 
70 
(63-
76) 
73 
(65–
78) 
73 (65–
78) 
72 
(64–
78) 
72 
(64–
78) 
76 (71-
81) 
Comorbidities         
 
Hypertension 4795 
(78.9) 
4750 
(78.9) 
7962 
(87.3) 
7954 
(87.6) 
6436 
(90.3) 
6474 
(90.8) 
6591 
(93.7) 
6588 
(93.6) 
1116 
(82.0) 
Diabetes mellitus 1402 
(23.1) 
1410 
(23.4) 
2284 
(25.0) 
2263 
(24.9) 
2878 
(40.4) 
2817 
(39.5) 
2559 
(36.4) 
2521 
(35.8) 
363 
(26.7) 
Heart failure 1934 
(31.8) 
1922 
(31.9) 
3235 
(35.5) 
3216 
(35.4) 
4467 
(62.6) 
4441 
(62.3) 
4097 
(58.2) 
4048 
(57.5) 
429 
(31.5) 
Previous stroke 1233 
(20.3) 
1195 
(19.8) 
1748 
(19.2) 
1790 
(19.7) 
3916 
(54.9) 
3895 
(54.6) 
1976 
(28.1) 
1991 
(28.3) 
267 
(19.6) 
Renal disease           
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eGFR > 80 
ml/min 
1945 
(32.2) 
1941 
(32.5) 
3761 
(41.2) 
3757 
(41.4) 
2285 
(32.1) 
2222 
(31.2) 
2612 
(37.1) 
2595 
(36.9) 
954 
(70.1) 
eGFR 80-50 
ml/min 
2852 
(47.3) 
2898 
(48.5) 
3817 
(41.9) 
3770 
(41.5) 
3298 
(46.2) 
3400 
(47.6) 
2985 
(42.4) 
3030 
(43.1) 
282 
(20.7) 
eGFR< 50 
ml/min 
1232 
(20.4) 
1126 
(18.8) 
1502 
(16.5) 
1515 
(16.7) 
1490 
(20.8) 
1459(2
0.4) 
1287 
(18.2) 
1297 
(18.4) 61 (4.6) 
CHADS2  2.2±1.
2 
2.1±1
.1 
2.1±1.
1 
2.1±1.
1 
3.48±0
.94 
3.46±0.
95 
2.8±1.
0 
2.8±1.
0 
2.4±2.3 
Discontinuation 
rate 
21.2
% 
16.6
% 
25.3% 27.5% 23.7% 22.2% 34.4% 34.5% 
10.0% 
Follow-up 2 years 1.8 years 1.9 years 2.8 years 6.5 years 
eGFR: estimated glomerular filtration rate. VKA: Vitamin K antagonists. CHADS2 = Congestive 
heart failure or left ventricular dysfunction (1); Hypertension (1), Age ≥75 (1), Diabetes mellitus 
(1) and prior Stroke/TIA or systemic embolism (2). Numeric values are means ± standard 
deviation, median and interquartile range or number (percentage). 
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Table 2: Estimated effect of NOACs. 
 
 
Acenocoum
arol 
 
n (%/year) 
Dabig
atran 
150mg 
n 
(%/yea
r) 
Acenocouma
rol 
vs 
Dabigatran 
150 mg 
p value 
NNT 
Dabiga
tran 
110 mg 
n 
(%/yea
r) 
Acenocouma
rol 
vs 
Dabigatran 
110 mg 
p value 
NNT 
Apixa
ban 
 
n 
(%/ye
ar) 
Acenoco
umarol 
vs 
Apixaba
n 
p value 
N
N
T 
Stroke 
130 
(1.47) 
83 
(0.94) 
0.001 18
9 
119 
(1.35) 0.486 909 
103 
(1.16) 0.076 
3
2
3 
Myocardial 
Infarction 
76 
(0.86) 
105 
(1.19) 
0.031 30
3 
103 
(1.16) 0.043 323 
67 
(0.76) 0.452 
9
0
9 
All-cause mortality 
551 
(6.23) 
485 
(5.48) 
0.041 13
3 
502 
(5.67) 0.131 179 
490 
(5.54) 0.057 
1
4
5 
Cardiovascular 
mortality 
75 
(0.85) 64 
(0.72) 
0.351 
76
9 
68 
(0.77) 0.588 
117
6 
67 
(0.76) 0.502 
1
1
1
1 
Major bleeding 
250 
(2.83) 
233 
(2.63) 
0.439 50
0 
200 
(2.26) 0.018 185 
172 
(1.95) 0.001 
1
1
4 
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Gastrointestina
l bleeding 
97 
(1.10) 
146 
(1.65) 
0.002 18
8 
107 
(1.21) 0.483 
101
0 
87 
(0.98) 0.461 
8
3
3 
Intracranial 
haemorrhage 
78 
(0.88) 
31 
(0.35) 
<0.001 19
2 
24 
(0.27) <0.001 164 
33 
(0.37) <0.001 
1
9
6 
Net clinical 
outcome 
693 
(7.83) 
630 
(7.12) 
0.083 
14
3 
637 
(7.20) 0.125 181 
588 
(6.65) 0.033 
8
5 
NNT: Number needed to treat. Net clinical outcome was defined as the composite of stroke, 
major bleeding and all mortality. 
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Table 2: Estimated effect of NOACs (Continue). 
 
 
Acenocoum
arol 
 
n (%/year) 
Rivaroxa
ban 
 
n (%/year) 
Acenocoumaro
l 
vs Rivaroxaban 
p value 
NNT 
Edoxaba
n 60mg 
 
n 
(%/year) 
Acenocoumar
ol 
vs Edoxaban 
60 mg 
p value 
NNT 
Stroke 
130 
(1.47) 
111 
(1.25) 
0.221 423 
114 
(1.29) 
0.306 555 
Myocardial 
Infarction 
76 (0.86) 61 (0.69) 0.200 625 71 (0.80) 0.680 
200
0 
All-cause mortality 
551 
(6.23) 
507 
(5.73) 
0.176 200 
507 
(5.73) 
0.176 200 
Cardiovascular 
mortality 
75 (0.85) 67 (0.76) 0.502 1111 65 (0.73) 0.398 833 
Major bleeding 
250 
(2.83) 
260 
(2.94) 
0.657 588 
200 
(2.26) 
0.018 185 
Gastrointestinal 
bleeding 
97 (1.10) 
142 
(1.60) 
0.004 202 
119 
(1.35) 
0.134 400 
Intracranial 
haemorrhage 
78 (0.88) 52 (0.59) 0.022 384 36 (0.41) 0.001 213 
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Net clinical 
outcome 
693 
(7.83) 
- - - 
617 
(6.97) 
0.036 128 
NNT: Number needed to treat. Net clinical outcome was defined as the composite of stroke, major 
bleeding and all mortality. Data to calculated was no reported in ROCKET trial for rivaroxaban.  
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What is known about this topic 
- Therapy with vitamin K antagonists (VKAs) is highly effective for reducing risk of 
stroke and mortality but VKAs have a narrow therapeutic window. 
- Non-Vitamin K oral anticoagulants (NOACs) have been developed as generally 
effective and safe alternative to VKAs in AF patients 
-The potential impact and absolute effect of NOACs in “real world” optimally 
management of VKA AF patients is unknown. 
 
What does this paper add?  
- In an optimally acenocoumarol anticoagulated AF patients, estimated reductions in 
stroke, bleeding and net clinical outcomes with NOACs are evident. 
- The greatest efficacy for stroke and mortality estimated reduction was seen with 
dabigatran 150mg, and best expected safety with apixaban.  
- All NOACs showed an estimated significant reduction for intracranial haemorrhage. 
